Skip to content

Effect of Electrosurgery on Blood Loss and Intraoperative Transfusions in Musculoskeletal Tumor Surgery

Effect of Monopolar Tungsten Needle Electrodes and Teflon Coated Spatula Electrodes on Blood Loss and Intraoperative Transfusions in Musculoskeletal Tumor Surgery Compared to Conventional Surgical Knives and Stainless-Steel Electrodes

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05164809
Enrollment
150
Registered
2021-12-21
Start date
2021-10-01
Completion date
2022-02-28
Last updated
2022-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Loss, Surgical, Electrosurgery, Transfusion Rate, Tumororthopaedics

Brief summary

Resection of malign musculoskeletal tumors and reconstruction with large tumor prostheses often results in relevant blood loss requiring hemodynamic stabilization and transfusion. The use of novel electrosurgical electrodes is assessed retrospectively regarding the potential to reduce blood loss and the need for transfusions.

Detailed description

Background Resection of malign musculoskeletal tumors and reconstruction with large tumor prostheses often result in relevant blood loss requiring hemodynamic stabilization and transfusion. Since machine autotransfusion is contraindicated in tumor surgery, other measures are necessary to reduce intraoperative blood loss. Objectives Tungsten needle electrodes can be used to simultaneously cut skin and seal bleeding vessels for superficial dissection. Spatula electrodes coated with Teflon (polytetrafluoroethylene PTFE) are used for coagulation and dissection of deeper tissues. The coating reduces eschar build-up and thus smoke creation compared to conventional stainless-steel electrodes. This study assesses the effect of these novel electrodes on blood loss and transfusion rates. Methods: The investigators retrospectively investigate all cases of tumor resection and reconstruction with tumor prostheses that were operated five years before the introduction of the new electrodes (2012-2016) and five years after (2018-2021) by one single surgeon with over 25 years of experience. Data are extracted from digital patient records and analyzed by descriptive statistics and t-test for normally distributed data or Mann-Whitney test in case of non-normal distribution.

Interventions

DEVICEApplication of novel electrodes

Application of novel electrodes since 2017 for the dissection of extremity tumors in tumororthopedics

Sponsors

University Hospital Muenster
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients who received hemipelvectomy, hip disarticulation, or major tumor prosthesis implantation at our hospital between 2010 and 2021 * Operated by one single surgeon

Exclusion criteria

\- Implantation of a Megaprosthesis without history of tumor

Design outcomes

Primary

MeasureTime frameDescription
Blood lossduring surgerymonitored during surgery in the anaesthesiology protocol
Transfusion of red packed blood cellsduring surgerynumber of intraoperative units of packed red blood cells

Secondary

MeasureTime frameDescription
post surgical wound drainage5 days post surgeyassessed via recorded volume

Countries

Germany

Contacts

Primary ContactJan Puetzler, Medical doctor
jan.puetzler@ukmuenster.de00492518359232
Backup ContactJan Puetzler, edical doctor
jan.puetzler@ukmuenster.de00492518359232

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026